Revealing the manufacturer of dacomitinib/dacomitinib

Dacomitinib/Dacomitinib, this innovative oral cancer treatment drug, is produced by Pfizer, the world-renowned pharmaceutical giant. Pfizer, headquartered in New York, USA, focuses on the research and development, production and sales of various types of drugs. The company has always been committed to improving people's quality of life by providing better and more efficient medical solutions to patients around the world through scientific research and collaboration.

Dacomitinib, as a tyrosine kinase inhibitor, has excellent performance in enhancing the inhibitory effect of epidermal growth factor kinase domain, and can effectively improve the activity of drug-resistant mutant cell lines such as T790M. This drug is able to significantly reduce phosphorylation levels and cell viability, and therefore has significant efficacy in the treatment of adult non-small cell lung cancer. Of particular note, dacomitinib is designed for patients with specific mutations in the epidermal growth factor receptor (EGFR) protein gene.

In terms of use, the recommended dose of dacomitinib is 45 mg per dayby oral administration until disease progression or drug toxicity reaches an unacceptable level. This drug has been widely considered as a first-line drug for the treatment of patients with metastatic non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) exon 19 or exon 21 L858R substitution mutations. There is also clear guidance on dose adjustment for patients with different renal and hepatic function conditions: no dose adjustment is required for patients with mild and moderate renal impairment; dose adjustment for patients with severe renal impairment remains to be studied; and for patients with mild and moderate hepatic impairment, no dose adjustment is recommended.